Short Interest in Compass Therapeutics, Inc. (NASDAQ:CMPX) Increases By 17.9%

Compass Therapeutics, Inc. (NASDAQ:CMPX - Get Free Report) was the target of a large growth in short interest in the month of November. As of November 30th, there was short interest totalling 1,450,000 shares, a growth of 17.9% from the November 15th total of 1,230,000 shares. Approximately 1.7% of the company's stock are sold short. Based on an average daily volume of 487,900 shares, the days-to-cover ratio is presently 3.0 days.

Compass Therapeutics Trading Up 2.1 %

Shares of NASDAQ CMPX traded up $0.03 during midday trading on Monday, reaching $1.49. The company's stock had a trading volume of 330,202 shares, compared to its average volume of 439,364. The stock has a 50 day simple moving average of $1.67 and a 200-day simple moving average of $1.41. The stock has a market capitalization of $205.01 million, a price-to-earnings ratio of -4.03 and a beta of 0.89. Compass Therapeutics has a fifty-two week low of $0.77 and a fifty-two week high of $2.34.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.08) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.11) by $0.03. As a group, equities analysts anticipate that Compass Therapeutics will post -0.35 EPS for the current year.

Institutional Trading of Compass Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of CMPX. Renaissance Technologies LLC raised its position in Compass Therapeutics by 99.7% during the second quarter. Renaissance Technologies LLC now owns 140,600 shares of the company's stock worth $141,000 after acquiring an additional 70,200 shares in the last quarter. Rhumbline Advisers raised its holdings in shares of Compass Therapeutics by 10.3% in the 2nd quarter. Rhumbline Advisers now owns 131,789 shares of the company's stock valued at $132,000 after purchasing an additional 12,315 shares during the period. Vanguard Group Inc. lifted its stake in Compass Therapeutics by 1.7% in the 1st quarter. Vanguard Group Inc. now owns 4,152,197 shares of the company's stock valued at $8,221,000 after purchasing an additional 71,008 shares during the last quarter. Panagora Asset Management Inc. bought a new position in Compass Therapeutics during the second quarter worth about $68,000. Finally, Cubist Systematic Strategies LLC acquired a new position in Compass Therapeutics during the second quarter worth approximately $41,000. Institutional investors and hedge funds own 68.43% of the company's stock.

Wall Street Analyst Weigh In

CMPX has been the topic of several research analyst reports. Leerink Partners downgraded shares of Compass Therapeutics from an "outperform" rating to a "market perform" rating and dropped their target price for the stock from $5.00 to $4.00 in a report on Friday, November 15th. Leerink Partnrs cut shares of Compass Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Friday, November 15th. LADENBURG THALM/SH SH raised shares of Compass Therapeutics from a "neutral" rating to a "buy" rating and set a $5.00 target price for the company in a research note on Monday, September 16th. Finally, HC Wainwright reissued a "buy" rating and issued a $10.00 price target on shares of Compass Therapeutics in a research note on Monday, November 11th. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat, Compass Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus target price of $6.75.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.